Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

37results about How to "Safety profile" patented technology

Small-volume oral transmucosal dosage

ActiveUS20090131479A1Predictable and safe pharmacokinetic profileSafety profileBiocideNervous disorderPost operativeDrug activity
Small-volume oral transmucosal dosage forms or NanoTabs® comprising a predetermined amount of a pharmaceutically active drug are provided. Exemplary applications include use of the NanoTabs® to administer a drug for the treatment of acute, post-operative or breakthrough pain.
Owner:VERTICAL PHARMA

Use of relaxin to treat diseases related to vasoconstriction

The invention relates to methods of treating diseases related to vasodilation, generally comprising administering to an individual an effective amount of a pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females, and is therefore useful in treating a wide variety of diseases relating to vasoconstriction.
Owner:THE UNIVERSITY OF MEDICINE & DENTISTRY OF NEW JERSEY ROBERT WOOD JOHNSON MEDICAL SCHOOL +2

Methods of treating juvenile type 1 diabetes mellitus

InactiveUS20080227846A1Reducing chronic complicationReducing premature deathBiocideMetabolism disorderNewly diagnosedIslet cells
The present disclosure describes methods for treating or preventing Type 1 diabetes mellitus in juveniles, particularly in juveniles newly diagnosed with Type 1 diabetes. This prevention or treatment of Type 1 diabetes is achieved by administering one or more therapeutic agents to a juvenile in need, wherein the therapeutic agent is, for example, a competitive inhibitor of mevalonate synthesis, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, or an inducer of AMP protein kinase (AMPK) activity. In certain embodiments, juveniles with Type 1 diabetes are treated with an HMG-CoA reductase inhibitor such as a statin, thereby decreasing the destruction of islet cells, or maintaining endogenous insulin production, in the juvenile.
Owner:MUSC FOUND FOR RES DEV

Ciclesonide for the treatment of airway disease in horses

The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative or salt thereof, for the treatment of airway disease in horses, such as pulmonary disease, preferably recurrent airway obstruction (RAO), Summer Pasture Associated Obstructive Pulmonary disease (SPAOPD), and inflammatory airway disease (IAD).
Owner:BOEHRINGER LNGELHEIM VETMEDICA GMBH

Mu opioid receptor agonist analogs of the endomorphins

The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and / or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated amino acid and (ii) a D-amino acid substitution in position 2. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.
Owner:TULANE EDUCATIONAL FUND +1

New therapy for transthyretin-associated amyloidosis

ActiveUS20140296188A1Acceptable safety profileImprove bioavailabilityBiocideNervous disorderBenzoxazoleGallate
It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and / or treatment of trans-thyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and / or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
Owner:SOM INNOVATION BIOTECH

Therapy for transthyretin-associated amyloidosis

It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and / or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and / or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
Owner:SOM INNOVATION BIOTECH

Strain of pseudomonas putida and its use in the control of diseases caused by bacteria and fungi in plants

ActiveUS20200178541A1High and long lasting effectEffectively antagonizeBiocideBacteriaBiotechnologyPseudomonas putida
The present invention refers to the strain CECT8538 of Pseudomonas putida and mutants thereof, and the use of said strain as a pesticide in controlling plant diseases caused by fungi and bacteria. Further aspects of the invention relate to methods for preparing pesticidal compositions comprising said strain. Finally, the invention relates to a method for controlling various plant diseases caused by fungi and bacteria in a plant, comprising treating the plant and / or seed thereof or substrate used for growing said plant with the strain CECT8538 of P. putida or a composition including it.
Owner:FUTURECO BIOSCI

New Therapy for Transthyretin-Associated Amyloidosis

It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and / or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and / or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
Owner:SOM INNOVATION BIOTECH

Fabricating method of cobweb-shaped alarm net

Disclosed is a fabricating method of a cobweb-shaped alarm net. The cobweb-shaped alarm net is mainly composed of warps, wefts and an alarm device and is characterized in that the wefts are distributed spirally around the central point of a plurality of the warps to form the net body and connected with the alarm device. The cobweb-shaped alarm net is a bionic design, is mounted outside a window, has the functions of shearing-resistance, anti-creeping, burglar prevention and protective alarming, avoids accidental high-altitude falling of people or objects, has no influence on escaping and disaster relief and can be widely applied to various building storeys.
Owner:浙江创魏新材股份有限公司

Mu opioid receptor agonist analogs of the endomorphins

The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and / or chronic pain. Embodiments of the invention are directed to cyclic analogs of endomorphin. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.
Owner:THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND +1

Methods of treating juvenile type 1 diabetes mellitus

InactiveUS20080275104A1Reducing chronic complicationReducing premature deathBiocideChemical treatment enzyme inactivationType 1 diabetesInducer
The present disclosure describes methods for treating Type 1 diabetes mellitus in juveniles. This treatment of Type 1 diabetes is achieved by administering one or more therapeutic agents to a juvenile in need, wherein the therapeutic agent is, for example, a competitive inhibitor of mevalonate synthesis, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, or an inducer of AMP protein kinase (AMPK) activity. In certain embodiments, juveniles with Type 1 diabetes are treated with an HMG-CoA reductase inhibitor such as a statin.
Owner:MUSC FOUND FOR RES DEV

Roof adjuster of sail house

The invention provides an adjuster for adjusting the roof of a sail house, which comprises a fixed part which is fixedly arranged relative to the sail house and a movable part, wherein the movable part is provided with an adjusting part to form into a first motion direction and a second motion direction which can be self locked and adjusted relative to the fixed part and a lug boss or U cup-shaped tightening part which is contacted with a pull rod of the flexible roof; the fixed part is a fixed block with inner screw thread; the movable part is a rod with external screw thread; and the inner or external adjusting part arranged at the movable part realizes the screw thread motion connection between the fixed part and the movable part, thereby tensioning and loosening the flexible roof. Theadjuster has simple structure, low cost, simple and reliable operation and small use amount, only can be installed at the corner or the middle of the sail house, and can smoothly tension and loose the sail house with the flexible roof, thereby leading the sail house to have technical effects of beautiful appearance, safety and durability, etc.
Owner:劳斯伯格建筑科技(上海)有限公司

Strain of Pseudomonas putida and its use in the control of diseases caused by bacteria and fungi in plants

ActiveUS11332709B2High and long lasting effectEffectively antagonizeBiocideBacteriaBiotechnologyPseudomonas putida
The present invention refers to the strain CECT8538 of Pseudomonas putida and mutants thereof, and the use of said strain as a pesticide in controlling plant diseases caused by fungi and bacteria. Further aspects of the invention relate to methods for preparing pesticidal compositions comprising said strain. Finally, the invention relates to a method for controlling various plant diseases caused by fungi and bacteria in a plant, comprising treating the plant and / or seed thereof or substrate used for growing said plant with the strain CECT8538 of P. putida or a composition including it.
Owner:FUTURECO BIOSCI

Method for treating inflammation

ActiveUS11478464B1Reduce inflammatory cell infiltrationReduce edemaOrganic active ingredientsAntipyreticAcetic acidDihydropyridine
A method of treating inflammation includes administering an anti-inflammatory agent to a patient in need thereof. The anti-inflammatory agent is selected from Compound 1 ([(2-{[3-(4-methyl-1H-benzimidazol-2-yl)piperidin-1-yl]carbonyl}phenyl) amino] acetic acid) and Compound 2 (Ethyl-1-(5-cyano-2-hydroxyphenyl)-4-oxo-5-phenoxy-1,4-dihydropyridine-3-carboxylate). Compound 1 and Compound 2 selectively inhibit COX-2 enzyme, without substantially inhibiting COX-1 enzyme, in contrast to many other NSAIDs.
Owner:KING FAISAL UNIV

Unit common-rail pump assembly for single cylinder diesel

The invention provides a unit common-rail pump assembly for a single cylinder diesel. The unit common-rail pump assembly for the single cylinder diesel comprises a pump body, a main valve seat detachably connected with the pump body, and an oil inlet structure arranged on the main valve seat, wherein a low-pressure oil cavity communicating with the oil inlet structure is arranged in the main valveseat; a proportional electromagnetic valve for controlling the oil inlet amount of the oil inlet structure is arranged in the low-pressure oil cavity; a pump head part communicating with the low-pressure oil cavity and used for oil inlet conveying control is arranged on the pump body; a plunger sleeve connected with the pump head part is arranged on the pump body and is provided with a high-pressure oil cavity communicating with an oil inlet cavity and an oil outlet cavity of the pump head part so as to push oil into the oil outlet cavity; a plunger movably connected with the inner wall of the plunger sleeve and used for providing a pushing force is arranged in the high-pressure oil cavity, and is connected with a drive shaft; and the pump head part is connected with an external oil pipe.Through the unit common-rail pump assembly for the single cylinder diesel provided by the invention, the production cost can be effectively reduced, and the reliability and the service life are improved.
Owner:珠海安瑾动力科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products